LenioBio GmbH

LenioBio GmbH develops and commercializes ALiCE® (Almost Living Cell-Extract), a proprietary cell-free protein expression platform. The technology enables rapid, efficient, and scalable production of a wide range of proteins, including complex ones, for research, drug discovery, vaccine development, and biomanufacturing. LenioBio aims to simplify biomanufacturing processes and accelerate the delivery of life-saving medicines.